menu
    • menu

    Find Nivolumab manufacturers, exporters & distributors on PharmaCompass

    NEW Prospects: 146
    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Virtual Booth

    Contact Supplier

    Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    4

    API Suppliers

    0

    USDMF

    0

    CEP/COS

    0

    JDMF

    0

    EU WC

    0

    KDMF

    0

    NDC API

    0

    VMF

    4

    Listed Suppliers

    0INTERMEDIATES

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    0

    Others

    FINISHED DOSAGE FORMULATIONS

    65

    FDF Dossiers

    6

    FDA Orange Book

    31

    Europe

    4

    Canada

    24

    Australia

    0

    South Africa

    0

    Listed Dossiers

    146PROSPECTS

    893DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    54RELATED EXCIPIENT COMPANIES

    110EXCIPIENTS BY APPLICATIONS

    PATENTS & EXCLUSIVITIES

    0

    US Patents

    0

    US Exclusivities

    5

    Health Canada Patents

    GLOBAL SALES INFORMATION

    US Medicaid

    55,620,147

    Annual Reports

    72,807

    Regulatory FDF Prices

    NA

    MARKET PLACE

    6

    API

    5

    FDF

    DIGITAL CONTENT

    2

    Data Compilation #PharmaFlow

    1

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    660

    News #PharmaBuzz

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set

    Listed Suppliers

    read-more
    read-more

    01

    LGM Pharma

    U.S.A
    arrow
    CPhI North America
    Booth #730
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothLGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Contact Supplier Contact Supplier
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Nivolumab

    About the Company : LGM Pharma is a global leader in sourcing APIs, including hard-to-find drug substances, for pharmaceutical and biotech industries. LGM also operates as a full-service drug product ...

    LGM Pharma is a global leader in sourcing APIs, including hard-to-find drug substances, for pharmaceutical and biotech industries. LGM also operates as a full-service drug product CDMO, offering formulation, analytical method development and testing, regulatory support, and commercial manufacturing. Supported by a network of over 220 accredited cGMP manufacturing partners and more than 100,000 sq. ft. of FDA-inspected cGMP manufacturing and warehouse space, LGM delivers secure, end-to-end solutions across multiple dosage forms. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
    LGM Pharma CB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Shanghai Minbiotech

    China
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothShanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.

    Contact Supplier Contact Supplier
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Nivolumab

    About the Company : Shanghai Minbiotech is specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square meters of R&D centers in...

    Shanghai Minbiotech is specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square meters of R&D centers in Nantong, Jiangsu and Jinan, Shandong, with more than 13,000㎡ of production sites. While supplying products to customers, the company also provides services such as technology development, technology transfer and technology exchange, aiming to provide customers with comprehensive supply and solutions in the biomedical industry. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
    Shanghai Minbiotech CB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    KinBio

    Israel
    PEGS Boston Summit
    Not Confirmed
    arrow

    KinBio

    Israel
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Israel
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Nivolumab

    About the Company : KinBio is a rapidly growing biopharmaceutical company based in Rehovot, Israel, with its main focus on developing needed therapies as well as offering a wide range of CDMO services...

    KinBio is a rapidly growing biopharmaceutical company based in Rehovot, Israel, with its main focus on developing needed therapies as well as offering a wide range of CDMO services – from concept to product. KinBio’s main focus is to pursue opportunities in the global pharmaceutical market. Augmented by a global group of affiliated companies, Kinbio specializes in research, development, manufacturing and commercialization of biopharmaceutical products. Kinbio’s commitment to top standard quality is inherent across the entire global organization, from our FDA approved cGMP sites to our state of the art R&D laboratories.
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Nanogen Pharmaceutical Biotechnolog...

    Vietnam
    PEGS Boston Summit
    Not Confirmed
    arrow

    Nanogen Pharmaceutical Biotechnolog...

    Vietnam
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Vietnam
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Nivolumab

    About the Company : Established in 1997, Nanogen Pharmaceutical Biotechnology JSC has been striving to become a world-class innovative biotechnology company in the pharmaceutical industry. We are pro...

    Established in 1997, Nanogen Pharmaceutical Biotechnology JSC has been striving to become a world-class innovative biotechnology company in the pharmaceutical industry. We are proud to be the leading company in the Asia-Pacific region that successfully researched and developed Active Pharmaceutical Ingredients (APIs) and specific therapeutic products on the foundation of advanced recombinant DNA/protein technology.
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Drugs in Development

    read-more
    read-more
    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAxplora is your partner of choice for complex APIs.

    Novasep Secures Manufacturing Deal with US Biotech for ADC Drug Candidate

    Details:

    Through the agreement, Novosep will perform the process development of the XB002 ADC. which is being evaluated in the early-stage clinical trial studies for the treatment of non-small cell lung cancer and cervical cancer.


    Lead Product(s): XB002,Nivolumab

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Antibody-drug Conjugate

    Sponsor: Exelixis

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement July 06, 2021

    Axplora CB

    01

    Axplora

    Germany
    arrow
    CPhI Milan
    Booth #3C1
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAxplora is your partner of choice for complex APIs.

    Lead Product(s) : XB002,Nivolumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Exelixis

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Novasep Secures Manufacturing Deal with US Biotech for ADC Drug Candidate

    Details : Through the agreement, Novosep will perform the process development of the XB002 ADC. which is being evaluated in the early-stage clinical trial studies for the treatment of non-small cell lung cancer and cervical cancer.

    Product Name : Undisclosed

    Product Type : Antibody-drug Conjugate

    Upfront Cash : Undisclosed

    July 06, 2021

    Axplora CB

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell ...

    Details:

    Nivolumab is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Small Cell Lung Carcinoma.


    Lead Product(s): Nivolumab,Rovalpituzumab Tesirine

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase I/ Phase IIProduct Type: Antibody, Unconjugated

    Sponsor: Bristol Myers Squibb

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable January 20, 2017

    Abbvie Company Banner

    02

    AbbVie Inc

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Nivolumab,Rovalpituzumab Tesirine

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Partner/Sponsor/Collaborator : Bristol Myers Squibb

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without ...

    Details : Nivolumab is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Small Cell Lung Carcinoma.

    Product Name : Undisclosed

    Product Type : Antibody, Unconjugated

    Upfront Cash : Inapplicable

    January 20, 2017

    Abbvie Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cance...

    Details:

    Pemetrexed is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.


    Lead Product(s): Pemetrexed,Nivolumab,Paclitaxel,Veliparib,Carboplatin

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Cytotoxic Drug

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable October 25, 2016

    Abbvie Company Banner

    03

    AbbVie Inc

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pemetrexed,Nivolumab,Paclitaxel,Veliparib,Carboplatin

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants...

    Details : Pemetrexed is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

    Product Name : Undisclosed

    Product Type : Cytotoxic Drug

    Upfront Cash : Inapplicable

    October 25, 2016

    Abbvie Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A 2-part Phase 1/2 Open-label Trial on ODM-212

    Details:

    ODM-212 is a small molecule drug, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of mesothelioma.


    Lead Product(s): ODM-212,Ipilimumab,Nivolumab,Gemcitabine,Paclitaxel,Sotorasib

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable May 04, 2026

    Fermion Orion Company Banner

    04

    Orion Corporation

    Finland
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : ODM-212,Ipilimumab,Nivolumab,Gemcitabine,Paclitaxel,Sotorasib

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A 2-part Phase 1/2 Open-label Trial on ODM-212

    Details : ODM-212 is a small molecule drug, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of mesothelioma.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    May 04, 2026

    Fermion Orion Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial

    Details:

    Nivolumab is a antibody drug, which is currently being evaluated in Phase II clinical studies for the treatment of melanoma, cutaneous malignant.


    Lead Product(s): Nivolumab,Inapplicable

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Antibody, Unconjugated

    Sponsor: The Wayne D. Kuni and Joan E. Kuni Foundation

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable May 08, 2026

    blank

    05

    Fred Hutchinson Cancer Center

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed

    Fred Hutchinson Cancer Center

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Nivolumab,Inapplicable

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : The Wayne D. Kuni and Joan E. Kuni Foundation

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFO...

    Details : Nivolumab is a antibody drug, which is currently being evaluated in Phase II clinical studies for the treatment of melanoma, cutaneous malignant.

    Product Name : Undisclosed

    Product Type : Antibody, Unconjugated

    Upfront Cash : Inapplicable

    May 08, 2026

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esoph...

    Details:

    Denikitug is a antibody drug, which is currently being evaluated in Phase II clinical studies for the treatment of stomach neoplasms.


    Lead Product(s): Denikitug,Nivolumab,Ramucirumab,Paclitaxel

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Antibody, Unconjugated

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable April 23, 2026

    blank

    06

    Gilead Sciences

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed

    Gilead Sciences

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Denikitug,Nivolumab,Ramucirumab,Paclitaxel

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastat...

    Details : Denikitug is a antibody drug, which is currently being evaluated in Phase II clinical studies for the treatment of stomach neoplasms.

    Product Name : Undisclosed

    Product Type : Antibody, Unconjugated

    Upfront Cash : Inapplicable

    April 23, 2026

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer

    Details:

    BMS-986504 (Navlimetostat) is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of mesothelioma, malignant.


    Lead Product(s): Mrtx-1719,Ipilimumab,Nivolumab,Fluorouracil,Calcium Folinate,Oxaliplatin,Gemcitabine,Platinum

    Therapeutic Area: Oncology Brand Name: BMS-986504

    Study Phase: Phase IProduct Type: Miscellaneous

    Sponsor: Bristol Myers Squibb

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable April 16, 2026

    blank

    07

    Memorial Sloan Kettering Cancer Center

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed

    Memorial Sloan Kettering Cancer Center

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Mrtx-1719, Ipilimumab, Nivolumab, Fluorouracil, Calcium Folinate

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Bristol Myers Squibb

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer

    Details : BMS-986504 (Navlimetostat) is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of mesothelioma, malignant.

    Product Name : BMS-986504

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    April 16, 2026

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer

    Details:

    Denikitug is a antibody drug, which is currently being evaluated in Phase II clinical studies for the treatment of colorectal neoplasms.


    Lead Product(s): Denikitug,Nivolumab,Bevacizumab,Trifluridine,Tipiracil Hydrochloride

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Antibody, Unconjugated

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable April 14, 2026

    blank

    08

    Gilead Sciences

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed

    Gilead Sciences

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Denikitug,Nivolumab,Bevacizumab,Trifluridine,Tipiracil Hydrochloride

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Adv...

    Details : Denikitug is a antibody drug, which is currently being evaluated in Phase II clinical studies for the treatment of colorectal neoplasms.

    Product Name : Undisclosed

    Product Type : Antibody, Unconjugated

    Upfront Cash : Inapplicable

    April 14, 2026

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Phase II Study of Ficerafusp Alfa in Combination With Nivolumab in Patients With Platinum-refractory Head and Neck Squamous Cell Carcinoma

    Details:

    Ficerafusp Alfa is a antibody-protein conjugate drug, which is currently being evaluated in Phase II clinical studies for the treatment of squamous cell carcinoma of head and neck.


    Lead Product(s): Ficerafusp Alfa,Nivolumab

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Antibody-protein Conjugate

    Sponsor: Bicara Therapeutics

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable April 14, 2026

    blank

    09

    GORTEC

    Country
    arrow
    PEGS Boston Summit
    Not Confirmed

    GORTEC

    Country
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Ficerafusp Alfa,Nivolumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Bicara Therapeutics

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Phase II Study of Ficerafusp Alfa in Combination With Nivolumab in Patients With Platinum-refracto...

    Details : Ficerafusp Alfa is a antibody-protein conjugate drug, which is currently being evaluated in Phase II clinical studies for the treatment of squamous cell carcinoma of head and neck.

    Product Name : Undisclosed

    Product Type : Antibody-protein Conjugate

    Upfront Cash : Inapplicable

    April 14, 2026

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors

    Details:

    HLX18 (Nivolumab) is a antibody drug, which is currently being evaluated in Phase I clinical studies for the treatment of esophageal neoplasms.


    Lead Product(s): Nivolumab,Inapplicable

    Therapeutic Area: Oncology Brand Name: HLX18

    Study Phase: Phase IProduct Type: Antibody, Unconjugated

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable April 08, 2026

    blank

    10

    Shanghai Henlius Biotech

    China
    arrow
    PEGS Boston Summit
    Not Confirmed

    Shanghai Henlius Biotech

    China
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Nivolumab,Inapplicable

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX18 ...

    Details : HLX18 (Nivolumab) is a antibody drug, which is currently being evaluated in Phase I clinical studies for the treatment of esophageal neoplasms.

    Product Name : HLX18

    Product Type : Antibody, Unconjugated

    Upfront Cash : Inapplicable

    April 08, 2026

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Europe

    read-more
    read-more

    01

    Bristol-Myers Squibb Sa

    U.S.A
    PEGS Boston Summit
    Not Confirmed
    arrow

    Bristol-Myers Squibb Sa

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Allowed

    Registration Country : Switzerland

    Nivolumab

    Brand Name : Opdivo

    Dosage Form : Concentrate For Solution For Infusion

    Dosage Strength : 40mg/4ml

    Packaging :

    Approval Date : 30/11/2015

    Application Number : 65660

    Regulatory Info : Allowed

    Registration Country : Switzerland

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Bristol-Myers Squibb Sa

    U.S.A
    PEGS Boston Summit
    Not Confirmed
    arrow

    Bristol-Myers Squibb Sa

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Allowed

    Registration Country : Switzerland

    Nivolumab

    Brand Name : Opdivo

    Dosage Form : Concentrate For Solution For Infusion

    Dosage Strength : 100mg/10ml

    Packaging :

    Approval Date : 30/11/2015

    Application Number : 65660

    Regulatory Info : Allowed

    Registration Country : Switzerland

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Bristol-Myers Squibb Pharma EEIG

    U.S.A
    PEGS Boston Summit
    Not Confirmed
    arrow

    Bristol-Myers Squibb Pharma EEIG

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Marketed

    Registration Country : Norway

    Nivolumab

    Brand Name : Opdivo

    Dosage Form : Solution For Injection

    Dosage Strength : 600mg

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info : Marketed

    Registration Country : Norway

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Bristol-Myers Squibb Pharma EEIG

    U.S.A
    PEGS Boston Summit
    Not Confirmed
    arrow

    Bristol-Myers Squibb Pharma EEIG

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Marketed

    Registration Country : Norway

    Nivolumab

    Brand Name : Opdivo

    Dosage Form : Concentrate For Solution For Infusion

    Dosage Strength : 10mg/ml

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info : Marketed

    Registration Country : Norway

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Bristol-Myers Squibb Pharma Eeig

    U.S.A
    PEGS Boston Summit
    Not Confirmed
    arrow

    Bristol-Myers Squibb Pharma Eeig

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Prescription

    Registration Country : Estonia

    Nivolumab; Relatlimab

    Brand Name : Opdualag

    Dosage Form : Concentrate For Solution For Infusion

    Dosage Strength : 240mg/20ml; 80mg/20ml

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info : Prescription

    Registration Country : Estonia

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Bristol-Myers Squibb Pharma Eeig

    U.S.A
    PEGS Boston Summit
    Not Confirmed
    arrow

    Bristol-Myers Squibb Pharma Eeig

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Prescription

    Registration Country : Estonia

    Nivolumab

    Brand Name : Opdivo

    Dosage Form : Concentrate For Solution For Infusion

    Dosage Strength : 10mg/ml

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info : Prescription

    Registration Country : Estonia

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Bristol-Myers Squibb Pharma Eeig

    U.S.A
    PEGS Boston Summit
    Not Confirmed
    arrow

    Bristol-Myers Squibb Pharma Eeig

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Authorized

    Registration Country : Spain

    Nivolumab

    Brand Name : Opdivo

    Dosage Form : Concentrate For Infusion Solution

    Dosage Strength : 10MG

    Packaging :

    Approval Date : 06-07-2015

    Application Number : 1151014001

    Regulatory Info : Authorized

    Registration Country : Spain

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Bristol-Myers Squibb Pharma Eeig

    U.S.A
    PEGS Boston Summit
    Not Confirmed
    arrow

    Bristol-Myers Squibb Pharma Eeig

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Authorized

    Registration Country : Spain

    Nivolumab

    Brand Name : Opdivo

    Dosage Form : Concentrate For Solution For Infusion

    Dosage Strength : 10MG

    Packaging :

    Approval Date : 03-09-2025

    Application Number : 1151014002IP2

    Regulatory Info : Authorized

    Registration Country : Spain

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Bristol-Myers Squibb Pharma Eeig

    U.S.A
    PEGS Boston Summit
    Not Confirmed
    arrow

    Bristol-Myers Squibb Pharma Eeig

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Prescription

    Registration Country : Denmark

    Nivolumab; Relatlimab

    Brand Name : Updualag

    Dosage Form : Concentrate For Solution For Infusion

    Dosage Strength : 240mg; 80mg

    Packaging :

    Approval Date : 15-09-2022

    Application Number : 28106676821

    Regulatory Info : Prescription

    Registration Country : Denmark

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Bristol-Myers Squibb Pharma Eeig

    U.S.A
    PEGS Boston Summit
    Not Confirmed
    arrow

    Bristol-Myers Squibb Pharma Eeig

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Prescription

    Registration Country : Denmark

    Nivolumab

    Brand Name : Opdivo

    Dosage Form : Concentrate For Solution For Infusion

    Dosage Strength : 240mg/24ml

    Packaging :

    Approval Date : 17-05-2018

    Application Number : 28106129218

    Regulatory Info : Prescription

    Registration Country : Denmark

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Fillers, Diluents & Binders

    read-more
    read-more

    Parenteral

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Topical

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Granulation

    read-more
    read-more

    Surfactant & Foaming Agents

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    Controlled & Modified Release

    read-more
    read-more

    Rheology Modifiers

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more

    STOCK RECAP #PipelineProspector

    read-more
    read-more

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search